Employee drug testing for cannabinoids: What you should know

by Duncan Fisher

August 31, 2022 - 2 min read

Mandatory drug testing is common in the workplace. A tempting workaround for consumers of therapeutic cannabinoids, such as CBD, is to reach for ‘synthetics’, thinking they do not contain THC, the psychoactive component of cannabis or cannabis-derived products. 

The truth is that synthetic CBD, if its extraction source was the cannabis plant, does contain trace amounts of THC. Removing it completely from the end-product is enormously difficult, and also time-consuming and costly. 

This unintentional residue, even in small amounts, can cause problems in drug testing. The solution is to use CBD that derives from a source that isn’t marijuana. 

We don’t use marijuana at PureForm. That’s why our wellness and pharmaceutical products are free of cannabis-related regulatory scrutiny. We transform aromatic terpene oils from other plant sources into pure – really pure – CBD, entirely free of THC – and also free of any of the plant pesticides, microbial contaminants, or heavy metals that can also come with agricultural cannabis production. 

This process is so good that PureForm has been awarded the Purity Award and the THC Free Award from the prestigious Clean Label Project, an industry watchdog dedicated to transparency and consumer safety. 

DiolPure products whose active ingredient is PureForm CBD can be used with no risk at all of accidental detection of THC or any other unwanted molecule in drug testing. 



DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 


The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 


Cannabigerol (CBG): Another promising cannabinoid?

Cannabigerol (CBG): Another promising cannabinoid?

For some good reasons, research and commercial attention is beginning to turn to cannabigerol, or 'CBG'. 
Read More

October 04, 2022 2 min read

Up close: Cannabinoids in Huntington's chorea

Up close: Cannabinoids in Huntington's chorea

In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time, show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream. 
Read More

October 03, 2022 3 min read

Up close: Cannabinoids in neurodegenerative diseases

Up close: Cannabinoids in neurodegenerative diseases

Modulation of cannabinoid receptor signaling should represent a viable therapeutic target in neurodegenerative diseases. 
Read More

September 30, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00
Shipping
Total

Shipping Address

Shipping Methods